Phase 3 Coronary Slow Flow Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Completed
Phase 2Phase 3
The anti-anginal effect of Zibotentan in the Coronary Slow Flow Phenomenon (CSFP)
Coronary Slow Flow Phenomenon
The University of Adelaide50 enrolled1 locationACTRN12618000021279
Recruiting
Phase 2Phase 3
Placebo controlled,randomised,crossover study of the efficacy of bosentan in the management of patients with Coronary Slow Flow Phenemenon
Coronary Slow Flow Phenomenon
Cenral Northern Adelaide Health Service - The Queen Elizabeth Hospital26 enrolled1 locationACTRN12608000236392
Completed
Phase 2Phase 3
Placebo controlled,randomised,crossover study of the efficacy of dipyridamole in the management of angina in patients with Coronary Slow Flow Phenomenon
Coronary Slow Flow Phenomenon
The Queen Elizabeth Hospital,Cardiology Unit16 enrolled1 locationACTRN12606000236594